Caribou Biosciences (CRBU) Expected to Announce Quarterly Earnings on Monday

Caribou Biosciences (NASDAQ:CRBU) is expected to announce its earnings results before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter.

Caribou Biosciences Stock Performance

NASDAQ CRBU opened at $1.16 on Friday. Caribou Biosciences has a 12 month low of $1.01 and a 12 month high of $7.61. The stock’s 50 day moving average is $1.43 and its 200 day moving average is $1.82. The stock has a market cap of $105.04 million, a PE ratio of -0.70 and a beta of 2.34.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Citigroup reduced their price objective on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, November 26th. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Caribou Biosciences in a research note on Friday, November 15th. Finally, Bank of America reduced their price objective on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $10.33.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.